New Research Sheds Light on Improved Lung Cancer Survival Rates
Special to the FMA from AdventHealth | July 24, 2023
Tuesday, Aug. 1, is World Lung Cancer Day. For those with advanced non-small cell lung cancer (NSCLC), having an inflammatory side effect, called an immune-related adverse event (irAE), from a monoclonal antibody treatment correlates with patients living longer, according to findings in a recent JAMA article co-written by Mark Socinski, MD, thoracic medical oncologist and executive medical director of the AdventHealth Cancer Institute.
The big picture
The American Society of Clinical Oncology lists NSCLC as the most common type of lung cancer in the U.S., accounting for 82% of all lung cancer diagnoses. For people with localized NSCLC, which means the cancer has not spread outside the lung, the overall five-year survival rate is 63%.
In advanced NSCLC, the standard of care treatment in most patients is the combination of chemotherapy plus immunotherapy. This new research shows that patients who have irAEs after introducing an immunotherapy drug, in this case a monoclonal antibody called atezolizumab, is directly linked to improved survival.
About the research
This published paper looked at three large, global phase 3 trials, all of which Dr. Socinski worked on, and asked the question:
If you had an immune-related adverse event (irAE), which means your immune system is turned
on and engaged, did the irAE correlate with survival of the patients?
“We found if you had a mild to moderate irAE, suggesting the immune system is invigorated, reactivated, no longer sleeping, and is fighting the cancer — that it controlled the cancer better,” Dr. Socinski said. “There was some spillover to normal tissue with some side effects, such as a rash, diarrhea and colitis, and that’s actually a good thing.”
If a patient’s irAEs consists of mild-to-moderate side effects, it’s not necessarily a bad thing, Dr. Socinski explained. Physicians have supportive care to manage and minimize these types of side effects, which can also indicate the immune system is engaged.
“It follows the paradigm of, ‘No pain, no gain,’ ” he said. “For example, having a rash might not be comfortable, but having an irAE means your immune system is in overdrive and working. If it’s working on your skin, then it’s also working on the cancer and controlling it.”
How it works
One of the hallmarks of cancer is the evasion of the immune system. There are a number of checkpoints that can turn on or turn off the immune system. In the last decade, the main checkpoint important to controlling cancer growth is the PD-1/-L1 pathway.
When the immune system locates certain tumors and attempts to attack it, the tumor expresses PD-L1 and puts the immune systems T Cells, which is a type of white blood cell, into a state of dormancy.
Blocking the PD-1/-L1 pathway with antibodies unlocks the immune system dormancy and wakes the T Cells up so they can fight the cancer. There are several monoclonal antibodies that can block the pathways, including atezolizumab, studied here.
In some cases, when the immune system is awakened, it attacks normal tissue, called immune-related adverse events (irAEs). Upon evaluation, this study concludes that mild to moderate irAE from monoclonal antibody treatments correlates with improvements in survival rates.
Currently, this type of immunotherapy treatment with mild to moderate irAEs is being studied by Dr. Socinski in a large database analysis to determine if it can be extended beyond lung cancer.
Question research as you read it and ask yourself, “Can it be taken a step further?” In addition, be creative in the way you come to your conclusion. Not every answer requires a clinical trial. Sometimes, as in this case, aggregating data and pooling analysis from multiple randomized clinical trials can help shed light on potential new treatment options.
To read the full JAMA-Oncology article, click here.